Eli Lilly and Company moved -2.3% this afternoon session, trading between a high of $537.29 and a low of $516.57 per share. Yesterday the stock finished at $538.29 per share, compared to an average analyst target price of $574.9.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The large-cap biotechnology: pharmaceutical preparations company is based in the United States, and over the last twelve months it has returned a dividend yield of 0.8%. Eli Lilly and Company has trailing twelve months earnings per share (EPS) of 7.2, which at today's prices amounts to a price to earnings (P/E) ratio of 73.1.
Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of 2.26. Usually a PEG ratio between 0 and 1 indicates a potentially undervalued company.
Overview of the Company's Gross Margins:
|Date Reported||Revenue ($ k)||Cost of Revenue ($ k)||Gross Margins (%)||YoY Growth (%)|
At 76.5%, Eli Lilly and Company's average gross margins are wider than the 60.94% average of its industry peer group, which suggests that the firm might have a competitive advantage.